<DOC>
	<DOCNO>NCT01194440</DOCNO>
	<brief_summary>RATIONALE : Zoledronic acid may prevent bone loss help prevent lessen musculoskeletal symptom woman receive hormone therapy breast cancer . PURPOSE : This phase II trial study well zoledronic acid work prevent musculoskeletal symptom post-menopausal woman stage I , stage II , stage III breast cancer receive letrozole .</brief_summary>
	<brief_title>Zoledronic Acid Aromatase Inhibitor Induced Musculoskeletal Symptoms</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Percentage woman experience aromatase inhibitor associate musculoskeletal symptom ( AIMSS ) 1 , 3 , 6 , 12 month bisphosphonate therapy , compare historical control . II . Change Health Assessment Questionnaire Disability Index ( HAQ-DI ) score 1 , 3 , 6 12 month , baseline , among receive bisphosphonate , compare historical control . SECONDARY OBJECTIVES : I . Change pain score visual analog scale ( VAS ) 1 , 3 , 6 12 month , baseline , compare historical control . II . Change amount and/or frequency oral analgesic use 1 , 3 , 6 12 month baseline among receive bisphosphonate therapy , compare historical control . III . Number patient discontinue change aromatase inhibitor ( AI ) therapy . IV . Change menopausal symptom ( NSABP-revised ) , hot flash frequency ( HFRDIS ) , sleep quality ( PSQI ) , depression score ( CESD ) overall quality life ( EuroQOL ) patient 1 , 3 , 6 12 month baseline , among receive bisphosphonate therapy , compare historical control . V. Changes plasma estrogen concentration 1 , 3 , 6 12 month baseline , among receive bisphosphonate therapy , compare historical control . VI . Change bone mineral density ( DEXA scan ) 12 month baseline , among receive bisphosphonate therapy , compare historical control . VII . Change bone turn marker ( serum-C telopeptide , bone-specific alkaline phosphatase , osteocalcin urinary N-telopeptide ) 1 , 3 , 6 12 month baseline , among receive bisphosphonate therapy , compare historical control . VIII . Change inflammatory marker ( ESR , CRP , IL-1 , IL-6 , IL-8 ) 1 , 3 , 6 12 month baseline , among receive bisphosphonate therapy , compare historical control . OUTLINE : Patients receive zoledronic acid intravenously ( IV ) month 1 6 . Beginning 14 day first zoledronic acid infusion , patient receive oral letrozole daily 12 month absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Inclusion Patients histologically proven DCIS stage IIII invasive carcinoma breast estrogen and/or progesterone receptor positive immunohistochemical stain consider aromatase inhibitor therapy ; woman may receive AI study initial adjuvant hormonal treatment follow tamoxifen ; patient must complete adjuvant chemotherapy ; patient may receive preoperative chemotherapy Postmenopausal status , define : &gt; = 60 year age ; &lt; 60 year age amenorrheic &gt; = 12 month prior day 1 intact uterus/ovaries ; &lt; 60 year age , last menstrual period 612 month prior day 1 , intact uterus/ovaries meet biochemical criterion menopause ( FSH estradiol within institutional standard postmenopausal status ) ; &lt; 60 year age , without uterus , meet biochemical criterion menopause ( FSH estradiol within institutional standard postmenopausal status ) ; &lt; 60 year age history bilateral oophorectomy ; prior radiation castration amenorrhea least 6 month ; &lt; 60 year age take medication design suppress ovarian function meet biochemical criterion menopause ( estradiol level within institutional standard postmenopausal status ; woman would take drug least 30 day prior day 1 ) ECOG performance status 02 Patient aware nature diagnosis , understand study regimen , requirement , risk , discomfort , able willing sign inform consent form Exclusion Concurrent use hormone replacement therapy Concurrent use tamoxifen ; patient take tamoxifen must discontinue drug prior first dose zoledronic acid Concurrent use selective estrogen receptor modulator ( SERM ) raloxifene Concurrent consumption soy supplement ; routine dietary consumption soy contain food permit Prior use aromatase inhibitor set Current bisphosphonate use ( oral intravenous ) ; prior bisphosphonate user would eligible long use &gt; 1 month ago oral bisphosphonates and/or &gt; 12 month ago intravenous bisphosphonates , prior start study treatment Moderate severe renal impairment ( serum creatinine great 2 mg/dL creatinine clearance le 50 mL/min ) Hypersensitivity letrozole zoledronic acid excipients Concomitant treatment oral intravenous corticosteroid Current active dental problem include infection teeth jawbone ( maxilla mandibular ) ; dental fixture trauma , current prior diagnosis osteonecrosis jaw ( ONJ ) , expose bone mouth , slow healing dental procedure Recent ( within 6 week ) plan dental jaw surgery ( e.g . extraction , implant )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>